Aligos Therapeutics Inc (ALGS) Stock Price, Quote & News

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a sm...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 466 6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States

biotrade123 Aug. 10 at 5:09 PM

$ALGS hopefull will hold the gains??

0 · Reply

wjk33 Aug. 10 at 4:45 PM

$ALGS hopefully just the begining. in Wainwright we trust.

0 · Reply

Stevenshb Aug. 10 at 4:34 PM

$ALGS Here’s one reason it’s going up: https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-aligos-stock-rating-on-hbv-progress-93CH-4848854?ampMode=1

0 · Reply

Suppandi Aug. 10 at 4:04 PM

$ALGS are we getting to the target of $175. Hope we do go to $50-$60 💪

0 · Reply

yodog941 Aug. 10 at 3:49 PM

$ALGS when trending

0 · Reply

ajmrtxl Aug. 10 at 3:48 PM

$ALGS 's latest data on SqueezeFinder

0 · Reply

yodog941 Aug. 10 at 3:44 PM

$ALGS let's fuxxing go

0 · Reply

IPOARMY1 Aug. 10 at 3:30 PM

$ALGS 👀👀

0 · Reply

biotrade123 Aug. 10 at 3:12 PM

$ALGS hmm.. board has little posts despite this making huge gains??

0 · Reply

IPOARMY1 Aug. 7 at 6:27 PM

$ALGS 👀

0 · Reply

Aligos Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 4 days ago

Aligos Therapeutics Quarterly report: Q2 2026

2026-08-06T13:21:38.000Z - 4 days ago

Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38)

Jul 30, 2026, 8:00 AM EDT - 11 days ago

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

2026-07-13T12:06:13.000Z - 4 weeks ago

Aligos Therapeutics completes enrollment in B-SUPREME study

Jul 13, 2026, 8:00 AM EDT - 4 weeks ago

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

2026-07-06T20:10:08.000Z - 4 weeks ago

Aligos Therapeutics receives $25M upfront for pevifoscorvir sodium license deal

Jul 6, 2026, 4:05 PM EDT - 4 weeks ago

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

2026-05-28T13:28:16.000Z - 2 months ago

Aligos Therapeutics initiated with a Buy at Lake Street

2026-05-27T09:15:09.000Z - 2 months ago

Aligos Therapeutics presents data at EASL congress

May 27, 2026, 2:30 AM EDT - 2 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

2026-05-21T11:02:51.000Z - 2 months ago

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-05-21T10:39:10.000Z - 2 months ago

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

May 13, 2026, 2:05 AM EDT - 3 months ago

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

May 7, 2026, 4:05 PM EDT - 3 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

May 7, 2026, 4:00 PM EDT - 3 months ago

Aligos Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 3 months ago

Aligos Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 4:05 PM EDT - 3 months ago

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Aligos Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Aligos Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-04-16T10:08:03.000Z - 4 months ago

Aligos Therapeutics signs license deal to develop pevifoscorvir in China

Apr 16, 2026, 6:00 AM EDT - 4 months ago

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

2026-04-14T20:18:56.000Z - 4 months ago

Aligos reports first interim analysis of B-SUPREME study, fast track designation

Apr 14, 2026, 4:05 PM EDT - 4 months ago

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Aligos Therapeutics Slides: Corporate presentation

2026-03-26T13:00:14.000Z - 4 months ago

Aligos Therapeutics initiated with a Buy at WestPark Capital

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Aligos Therapeutics Slides: Corporate presentation

2026-03-19T09:15:20.000Z - 5 months ago

Aligos Therapeutics assumed with a Buy at Jefferies

Mar 5, 2026, 9:30 AM EST - 5 months ago

Aligos Therapeutics Annual report: Q4 2025

Mar 5, 2026, 9:30 AM EST - 5 months ago

Aligos Therapeutics Earnings release: Q4 2025

2026-03-05T13:14:38.000Z - 5 months ago

Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 8:00 AM EST - 5 months ago

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

2026-02-23T13:16:07.000Z - 6 months ago

Aligos announces data from two presentations at CROI on pevifoscorvir sodium

Feb 23, 2026, 8:00 AM EST - 6 months ago

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

2026-01-21T13:10:22.000Z - 7 months ago

Aligos Therapeutics provides update for Phase 2 study of pevifoscorvir sodium

2026-01-21T13:10:14.000Z - 7 months ago

Aligos Therapeutics announces resignation of Chief Medical Officer Achneck

Jan 21, 2026, 8:00 AM EST - 7 months ago

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

2026-01-20T19:55:25.000Z - 7 months ago

Aligos Therapeutics management to meet virtually with Piper Sandler

2026-01-13T13:16:17.000Z - 7 months ago

Aligos Therapeutics appoints James Hassard as EVP, CCO

2026-01-07T13:21:19.000Z - 7 months ago

Aligos Therapeutics initiated with a Buy at UBS

APGE COGT IDYA IVA KOD SABS VTYX

Dec 11, 2025, 8:00 AM EST - 8 months ago

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Nov 17, 2025, 10:00 AM EST - 9 months ago

Aligos Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 9 months ago

Aligos Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Aligos Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Aligos Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:30 AM EDT - 10 months ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Oct 21, 2025, 7:00 AM EDT - 10 months ago

Aligos Therapeutics Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 16, 2025, 8:30 AM EDT - 10 months ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Oct 14, 2025, 8:30 AM EDT - 10 months ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Aligos Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Sep 2, 2025, 4:05 PM EDT - 1 year ago

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Aug 13, 2025, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Aligos Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q2 2025

Jul 30, 2025, 4:05 PM EDT - 1 year ago

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

Jun 5, 2025, 2:00 PM EDT - 1 year ago

Aligos Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

May 8, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

May 6, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Quarterly report: Q1 2025

May 6, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Registration statement: Registration Filing

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Annual report: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Feb 12, 2025, 7:00 AM EST - 1 year ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Dec 3, 2024, 4:15 PM EST - 1 year ago

Aligos Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 11:00 AM EST - 1 year ago

Aligos Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 1:30 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Nov 6, 2024, 4:00 PM EST - 1 year ago

Aligos Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Aligos Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aligos Therapeutics Registration statement: Registration Filing

Oct 8, 2024, 3:00 PM EDT - 1 year ago

Aligos Therapeutics Transcript: 8th Annual MASH Investor Conference

Oct 1, 2024, 8:00 AM EDT - 2 years ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Sep 30, 2024, 8:00 AM EDT - 2 years ago

Aligos Therapeutics to Present at Investor Conferences in October

Sep 19, 2024, 8:30 AM EDT - 2 years ago

Aligos Therapeutics Transcript: Study Result

Sep 19, 2024, 8:30 AM EDT - 2 years ago

Aligos Therapeutics Press release: Study Result

Sep 19, 2024, 8:30 AM EDT - 2 years ago

Aligos Therapeutics Slides: Study Result

Sep 19, 2024, 8:00 AM EDT - 2 years ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 18, 2024, 5:00 PM EDT - 2 years ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aug 15, 2024, 9:00 AM EDT - 2 years ago

Aligos Therapeutics Announces Reverse Stock Split

Aug 8, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Earnings release: Q2 2024

Jul 22, 2024, 9:00 AM EDT - 2 years ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jun 5, 2024, 2:30 AM EDT - 2 years ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

biotrade123 Aug. 10 at 5:09 PM

$ALGS hopefull will hold the gains??

0 · Reply

wjk33 Aug. 10 at 4:45 PM

$ALGS hopefully just the begining. in Wainwright we trust.

0 · Reply

Stevenshb Aug. 10 at 4:34 PM

$ALGS Here’s one reason it’s going up: https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-aligos-stock-rating-on-hbv-progress-93CH-4848854?ampMode=1

0 · Reply

Suppandi Aug. 10 at 4:04 PM

$ALGS are we getting to the target of $175. Hope we do go to $50-$60 💪

0 · Reply

yodog941 Aug. 10 at 3:49 PM

$ALGS when trending

0 · Reply

ajmrtxl Aug. 10 at 3:48 PM

$ALGS 's latest data on SqueezeFinder

0 · Reply

yodog941 Aug. 10 at 3:44 PM

$ALGS let's fuxxing go

0 · Reply

IPOARMY1 Aug. 10 at 3:30 PM

$ALGS 👀👀

0 · Reply

biotrade123 Aug. 10 at 3:12 PM

$ALGS hmm.. board has little posts despite this making huge gains??

0 · Reply

IPOARMY1 Aug. 7 at 6:27 PM

$ALGS 👀

0 · Reply

aletz Aug. 7 at 5:35 PM

$ALGS 4.34 -> 5.23 closed with a profit but this price action is giving me a FOMO 🤣🤣

0 · Reply

ALGSmoon Aug. 7 at 3:53 PM

$ALGS really strange price action today. 100k shares transacted. .10 over the bid.

0 · Reply

ALGSmoon Aug. 6 at 9:38 PM

$ALGS let's see if this stops being an "easy short".

1 · Reply

ZRN227 Aug. 6 at 6:05 PM

$ALGS The math is simple, with -$0.14/share earnings and $25 mil in the bank, ALGS is 100% profitable in 2026, $2-3/share. 25 mil came in 3rd Q, not reported yet. My estimates is $40-50 by Thanksgiving. https://www.tradingview.com/symbols/NASDAQ-ALGS/forecast-price-target/

1 · Reply

HedgeUrHedge Aug. 6 at 3:10 PM

$ALGS price target is now $800/share

1 · Reply

ajmrtxl Aug. 5 at 3:52 PM

$ALGS 's latest data on SqueezeFinder

0 · Reply

Uncle_Tom Aug. 5 at 8:29 AM

$ALGS Analyst Consensus - Piper Sandler (Rahimi): $175.00 - H.C. Wainwright (Trucchio): 75.00 - Jefferies (Li): $50.00 - Lake Street: $45.00 - Lucid Capital: $36.00 - USB: $20 Average: $56.29 - Dr. Yasmeen Rahimi (Piper Sandler): Top Expert. Ph.D. in Biochemistry (Indiana Univ.) + Postdoc (Yale Medicine). Former Shire Pharmaceuticals scientist. Deeply specialized in liver metabolism, making her the most authoritative voice on Aligos' science. - Anthea Li (Jefferies): Strong Foundation. B.A. in Biology and Immunology (UC Berkeley). Strong understanding of immune responses, critical for evaluating Aligos' Hepatitis B therapies. - Patrick Trucchio (H.C. Wainwright): Market Expert. Financial background (MBA). Over 14 years of biotech equity research, focusing on commercial execution and FDA regulatory pathways.

1 · Reply

Buyhighsellatlow Aug. 5 at 1:56 AM

$ALGS this could be an excellent short at the current price of $4.81. Gonna fade hard after earnings, history shows.

0 · Reply

Luckyizme Aug. 3 at 2:15 PM

$ALGS Will take small profit off the top. Er pops tend to fade

0 · Reply

JustBen47 Aug. 1 at 11:15 PM

$ALGS Looks ready for next week

0 · Reply

biotrade123 Jul. 31 at 2:44 PM

$ALGS deal(partnership) imminent? the only way forward??

1 · Reply

focafoca99 Jul. 30 at 12:26 PM

$ALGS looks ahead to its Q2 2026 results release on Aug 6.

0 · Reply

Market Cap	34.59M
Revenue (ttm)	2.19M
Net Income (ttm)	-24.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,104.57%
Debt to Equity Ratio	0.00

Volume	407,162
Avg Vol	187,680
Day's Range	N/A - N/A
Shares Out	6.19M
Stochastic %K	74%
Beta	2.31
Analysts	Strong Sell
Price Target	$56.28